Abstract: Type 2 DM is a prevailing chronic disease worldwide. It is associated with a number of complications and has very significant mortality and morbidity as well. The main pathophysiology of diabetes is the understanding of carbohydrate metabolism. Insulin resistance, mainly caused by obesity and physical inactivity, both precedes and predicts type 2 diabetes. This insulin resistance is commonly due to metabolic factors other than Weight, Fat distribution, Race, Inactivity, Family history, Age, Prediabetics, Areas of darkened skin, usually in the armpits and neck and Gestational diabetes. DM-2 is also associated with a number of complications like Heart and blood vessel disease, Nerve damage (neuropathy) and kidney damage. Metformin remains the first line and most effective medication, yet it is not the best use as a single drug regime in most of the patients. Nowadays the most effective treatment in Type 2DM is a combination of multiple oral hypoglycemic drugs. SGLT-2 Inhibitors and GLP-1 Agonist are some of the efficacious 2nd line treatments for Type 2 DM. One of the most important questions is what are the factors that should be taken into account to guide the choice between SGLT-2 inhibitors and GLP-1 Agonists. It is estimated that Both GLP-1 Agonist and SGLT-2 Antagonist are beneficial in reducing the number of complications especially associated with cardiovascular outcomes. SGLT-2 Inhibitors are particularly more efficacious in preventing cardiovascular risks.
Keywords: SGLT-2 Inhibitors, GLP-1, pathophysiology, cardiovascular risks.
Title: SGLT-2 Inhibitors and GLP-1 Receptor agonist on Cardiovascular mortality reduction
Author: Dr. Shivam Singla, Dr. Ashish Shrivastava, Dr. Aditya Keerthi Rayapureddy, Dr. Sarraa Aljalily, Dr. Chhaya Kamwal, Dr. Kirti Juneja, Dr. Vinesh Kumar, Dr. Anil A. Kumar, Dr. Tanya Aggarwal
International Journal of Healthcare Sciences
ISSN 2348-5728 (Online)
Research Publish Journals
